創薬流通市場「薬市楽座」
安土桃山時代に自由取引市場として発展した「楽市楽座」にあやかり、創薬シーズ・技術のマーケットプラットフォームを創薬流通市場、「薬市楽座」と名付けました。このマーケットが楽市楽座のように発展することを願っています。
創薬流通市場である薬市楽座では、弊社がお預かりしている創薬シーズ・技術の情報をリストアップしています。ご興味に応じて検索していただくことが可能です。また、リストのダウンロードも行っていただけます。ご興味のあるものがあれば、お問い合わせボタンをクリックしていただき、弊社へのコンタクトをお願いいたします。追加情報を開示させていただきます。
なお、2019年6月27日より、日本語ページにおける、創薬シーズ、創薬技術の各リスト表記が英語に変更になりました。ダウンロード用のPDF、エクセルファイルは英語ページよりダウンロードできる資料と同一ですので、予めご了承下さいませ。
| 掲載日 | シーズ番号 | 作用機序 | 適応症 | 投与経路 | モダリティ | 開発ステージ | 備考 | |
|---|---|---|---|---|---|---|---|---|
| 21/04/02 | GEM241 | Analyzer of EEG algorithm by AI | Prediction of seizures in epilepsy patients | Ear wearable | Medical device | On Market | ・A personalized ear-wearable non-invasive small medical device which detects changes in EEG pattern by AI algorithm that alerts seizure minimum one minute before it occurs to patients and caregivers. ・It records brain activities through the ear canal and uses Big Data. ・By predicting the seizure before it occurs, the device will prevent accidents and reduce injuries, emergencies, and deaths. ・Also, it reduces emotional impact such as anxiety/depression and increases de quality of life. ・Big Data treatment can help doctors and medical society to better understand the illness and perform patinets' follow-up. |
問合せ |
| 21/03/26 | GEM117 | Induction of apoptosis in adipocyte | Lipolysis, non-surgical fat reduction, Diabetes | s.c. | Small molecule |
Phase 2a completed | · GEM117 specifically induce apoptosis on local injection site adipocyte · Phase 1 showed great safety without drug-related SAE in 40 healthy volunteers · In the Phase 2a study (n=39), GEM117 showed significant dose-dependent lipolysis effects and reduced an average of 24% local fat volume. The safety profile was similar as observed in the Phase 1 study. |
問合せ |
| 21/03/24 | GEM240 | Genetically modified adipocytes | Genetic diseases and intractable diseases | Transー plant | Gene and Cell therapy | Phase 1 | Genetically modified adipocytes for gene therapy and regenerative therapy. It is developed for the treatment of various genetic diseases and metabolic disorders. It shows sustainable and stable efficacy or secretion of transduced gene products from the implant of GEM240. GEM240 is incomparable and patient-friendly. |
問合せ |
| 21/02/26 | GEM-CVD08 | An anti-SARS-COV-2 S1 RBD antibody | COVID-19 | i.v. | Protein | Phase-1 | > 10 fold higher binding affinity and >50 fold more potent blocking potency than soluble hACE2-Fc. Neutralize authentic SARS-COV-2 virus infection of Vero E2 cells at IC50 = 0.012 - 0.062 µg/ml. Showed binding and blocking activity against South Africa and UK mutants. Engineered Fc to reduce potential ADE risk. Obtained CHO-K1 CMC clone with high expression titer. Showed potent prophylactic and desired therapeutic efficacy in rhesus monkey disease model. |
問合せ |
| 21/02/03 | GEM155 | FPR2-specific ligand | Atopic dermatitis/ Psoriasis, Dry eye disease, IBD （Inflammatory bowel disease）, Asthma, Rheumatoid arthritis | Topical, Eye drop, s.c. | Peptide | Phase 1 | GEM155 is a small (7mer) lipidated peptide ligand for pro-resolving receptor FPR2 (N-formyl peptide receptor 2) involved in regulation of innate immune system and inhibition of ILC2 function (adaptive immune system). It also has anti-microbial effect for pathogenic bacteria through fusion with functional moiety. Efficacy is seen in animal models for the indications. CMC study is almost done. Toxicity study for topical usage and subcutaneous injection is going-on. Formulation for topical use is almost finished. | 問合せ |
| 21/01/29 | GEM067 | c-Kit inhibitor | Diabetic macular edema & Retinopathy | Oral | Small molecule |
Phase 2a completed | -Inhibits stem cell factor-induced hyperpermeability -Reverses retinal vascular leakage in STZ-induced diabetic rats -Improved compliance to administration (oral) than anti-VEGF therapy (intra-vitreal injection) -Applicable to non-responders to anti-VEGF therapy -Repositioning of a marketed drug |
問合せ |
| 21/01/29 | GEM105 | Viscosupplementation | Knee osteoarthritis | Intra-articular | Poly- saccharide |
Marketing authorization | Cross-linked sodium hyaluronate hydrogel with sodium hyaluronate fluid. Long-lasting and sustainable efficacy due to unique rheology of the cross-linked hydrogel. Injected only once and single injection shows comparable efficacy to a multiple-injection treatment. Obtained marketing authorization as a drug. | 問合せ |
| 21/01/13 | GEM239 | Activation of Treg and downregulating pro-inflammatory cytokines | Psoriasis, Psoriatic arthritis, Rheumatoid arthritis, Ankylosing spondylitis, Crohn's and colitis | Oral | Small molecule | Human POC completed | Microbiomes are important for regulating human immune systems. GEM239 is a small molecule known as a gut microbial metabolite. It downregulates pro-inflammatory cytokines, and promotes differentiation of anti-inflammatory Treg cells. Human POC study in small number of psoriasis patients has been done and significant treatment effects have been seen. FDA IND approved. Clinical trial starting in 30 patients. Formulation-science has been applied. | 問合せ |
| 21/01/06 | GEM238 | CSN5 inhibitor | Cancer | i.v. | Peptide | Preclinical | - Identifying CDK2 binding regions within the CSN5 protein - Specifically inhibits the binding between CSN5 and CDK2 in "small complex" that is specifically expressed in cancer cells. - It is possible to specifically inhibit the growth of cancer cells while suppressing the effect on normal cells. |
問合せ |
| 21/01/04 | GEM237 | Autologous chondrocyte cell therapy for cartilage repair/regeneration | Chondral and osteochondral articular lesions of the knee | Arthro- scopic implan- tation | Cell and scaffold | Launch | The autologous cartilage repair system （a device kit consisting of a bioabsorbable highly porous scaffold and an enzyme for processing removed a small amount of cartilage） is for one-step surgery. It does not require an ex vivo cell expansion process. Hyaline cartilage is regenerated and long-term effectiveness is superior to the marrow stimulation procedure. |
問合せ |